Edwards Lifesciences Corp

1. 01

   1.1% below its 52-week high

   Closed at $95.19 on 3 Nov 2026: 1.1% below the 52-week high of $96.29 (7 Jul 2026) and 27.5% above the low of $74.66 (11 Feb 2026).

   Daily price bars, split-adjusted · as of 3 Nov 2026

2. 02

   Ahead of SPY, behind its sector fund XLV over 1 year

   1 month: +9.1% (SPY −2.6%, XLV +9.9%). 3 months: +6.2% (SPY −2.2%, XLV +13.5%). 1 year: +14.6% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: EW, SPY and XLV · as of 3 Nov 2026

3. 03

   Volume 1.7× its 30-session average on 3 Nov 2026

   3 Nov 2026 volume of 6.6M shares was 1.7× the average of the 30 sessions before it (3.9M), as the price rose 2.1%. SPY traded 0.8× its own average that session.

   Daily volume against a 30-session baseline · as of 3 Nov 2026

4. 04

   Above its 50- and 200-day averages

   The 3 Nov 2026 close of $95.19 was 7.8% above its 50-day average ($88.31) and 11.3% above its 200-day average ($85.53). It has closed above the 200-day for 18 sessions, since 9 Oct 2026. The 50-day average crossed above the 200-day on 17 Apr 2025, 388 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026

5. 05

   Short interest at 1.6% of shares outstanding

   9.3M shares were sold short at the 15 Oct 2026 settlement, 1.6% of the 575.8M shares outstanding; covering them would take 2.5 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

At the 3 Nov 2026 close